Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338581 · ClinicalTrials.gov registry record · Phase 2
Evaluation of AMG 714 for Vitiligo
A Phase 2 study of Vitiligo, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT04338581 is a Phase 2 study of Vitiligo that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants, below the 1,120-participant average among 15 other Vitiligo trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT04338581, a Phase 2 study of Vitiligo, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AMG 714
- PROCEDURE nbUVB phototherapy
Study Locations (7)
California
- University of California, Irvine: Department of Dermatology - Irvine
- University of California Davis Health System: Department of Dermatology - Sacramento
Massachusetts
- Tufts Medical Center: Department of Dermatology - Boston
- University of Massachusetts Medical School - Worcester
Connecticut
- Yale University School of Medicine: Department of Dermatology - New Haven
Michigan
- Henry Ford Health System - Detroit
New York
- Northwell Health - Lake Success
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2025-04-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04338581
The ClinicalTrials.gov registry entry for NCT04338581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,120-participant average among 15 other Vitiligo trials with a reported enrollment target (95% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04338581 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04338581 about?
NCT04338581 is a clinical study titled "Evaluation of AMG 714 for Vitiligo". This study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
What is the current status of trial NCT04338581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-12-11. Estimated completion is 2025-04-02.
What conditions does trial NCT04338581 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT04338581?
The interventions under investigation include: Placebo (BIOLOGICAL), AMG 714 (BIOLOGICAL), nbUVB phototherapy (PROCEDURE).
Who is sponsoring clinical trial NCT04338581?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04338581 being conducted?
This trial has 7 study locations across California, Connecticut, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daily Topical Rapamycin for Vitiligo
ACTIVE NOT RECRUITING · Phase 2
-
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
COMPLETED · Phase 2
-
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
COMPLETED · Phase 2
-
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
COMPLETED · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.